APLT · Insider Trading
Applied Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by APLT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-04 | Stacy J. Kanter | Director | MIXED | −65,000 | — |
| 2026-02-03 | Jay S Skyler | Director | MIXED | −65,000 | — |
| 2026-02-03 | Leslie D. Funtleyder | Chief Financial Officer | MIXED | −1,340,459 | — |
| 2026-02-03 | Constantine Chinoporos | See Remarks | MIXED | −619,611 | — |
| 2026-02-03 | Evan Prescott Bailey | Chief Medical Officer | MIXED | −859,316 | — |
| 2026-02-03 | Corwin Dale Hooks | Chief Commercial Officer | MIXED | −555,753 | — |
| 2026-02-03 | Teena Lerner | Director | MIXED | −105,422 | — |
| 2026-01-02 | Leslie D. Funtleyder | Chief Financial Officer | A | +150,000 | — |
| 2025-12-18 | Stacy J. Kanter | Director | Sell | −43,000 | −$4.82K |
| 2025-10-01 | Leslie D. Funtleyder | Chief Financial Officer | A | +150,000 | — |
| 2025-07-03 | Leslie D. Funtleyder | Chief Financial Officer | A | +300,000 | — |
| 2025-06-17 | Evan Prescott Bailey | Chief Medical Officer | A | +300,000 | — |
| 2025-06-11 | Teena Lerner | Director | A | +200,000 deriv. | — |
| 2025-06-11 | Stacy J. Kanter | Director | A | +200,000 deriv. | — |
| 2025-06-11 | Jay S Skyler | Director | A | +200,000 deriv. | — |
| 2025-03-26 | Constantine Chinoporos | See Remarks | A | +350,000 | — |
| 2025-03-26 | Corwin Dale Hooks | Chief Commercial Officer | A | +250,000 | — |
| 2025-03-26 | Leslie D. Funtleyder | See Remarks | A | +350,000 | — |
| 2025-03-06 | Riccardo Perfetti | Chief Medical Officer | Sell | −10,366 | −$4.56K |
| 2025-03-06 | Constantine Chinoporos | See Remarks | Sell | −447 | −$197 |
| 2025-03-06 | Leslie D. Funtleyder | See Remarks | Sell | −14,502 | −$6.38K |
| 2025-02-07 | Riccardo Perfetti | Chief Medical Officer | Sell | −86,078 | −$52.51K |
| 2025-02-07 | Leslie D. Funtleyder | See Remarks | Sell | −22,950 | −$14.00K |
| 2025-02-07 | Constantine Chinoporos | See Remarks | Sell | −28,117 | −$17.15K |
| 2024-12-20 | John Johnson | Executive Chairman | A | +500,000 | — |
| 2024-12-20 | Leslie D. Funtleyder | See Remarks | A | +150,000 | — |
| 2024-08-23 | Riccardo Perfetti | Chief Medical Officer | Sell | −22,681 | −$132.23K |
| 2024-08-23 | Leslie D. Funtleyder | Chief Financial Officer | Sell | −13,530 | −$78.88K |
| 2024-08-14 | Shoshana Shendelman | President and CEO | MIXED | −777,014 | −$4.71M |
| 2024-06-10 | Riccardo Perfetti | Chief Medical Officer | Sell | −22,003 | −$95.05K |
| 2024-06-10 | Leslie D. Funtleyder | Chief Financial Officer | Sell | −16,980 | −$73.35K |
| 2024-06-10 | Shoshana Shendelman | President and CEO | Sell | −61,795 | −$266.95K |
| 2024-06-07 | Joel S Marcus | Director | A | +45,000 | — |
| 2024-06-07 | Jay S Skyler | Director | A | +45,000 | — |
| 2024-06-07 | Stacy J. Kanter | Director | A | +45,000 | — |
| 2024-06-07 | Teena Lerner | Director | A | +45,000 | — |
| 2024-06-06 | Alexandria Equities No. 7, LLC | 10%+ Owner | Sell | −900,000 | −$3.80M |
| 2024-04-15 | Corwin Dale Hooks | Chief Commercial Officer | A | +300,000 | — |
| 2024-03-18 | Riccardo Perfetti | Chief Medical Officer | Sell | −110,804 | −$597.23K |
| 2024-03-18 | Adam Hansard | Chief Commercial Officer | Sell | −48,871 | −$263.41K |
| 2024-03-18 | Constantine Chinoporos | See Remarks | A | +300,000 | — |
| 2024-03-18 | Shoshana Shendelman | President and CEO | Sell | −318,573 | −$1.72M |
| 2024-03-18 | Leslie D. Funtleyder | Chief Financial Officer | Sell | −28,727 | −$154.84K |
| 2023-12-22 | Riccardo Perfetti | Chief Medical Officer | A | +450,000 | — |
| 2023-12-22 | Adam Hansard | Chief Commercial Officer | A | +400,000 | — |
| 2023-12-22 | Shoshana Shendelman | President and CEO | A | +1,540,000 | — |
| 2023-12-05 | Stacy J. Kanter | Director | Buy | +30,000 | +$65.37K |
| 2023-12-01 | Adam Hansard | Chief Commercial Officer | Sell | −965 | −$1.90K |
| 2023-12-01 | Riccardo Perfetti | Chief Medical Officer | Sell | −1,583 | −$3.12K |
| 2023-12-01 | Shoshana Shendelman | President and CEO | Sell | −3,968 | −$7.82K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Evan Prescott Bailey | Chief Medical Officer | 1,296,816 | $133.57K |
| Riccardo Perfetti | Chief Medical Officer | 890,409 | $91.71K |
| John Johnson | Executive Chairman | 500,000 | $51.50K |
| Teena Lerner | Director | 82,922 | $8.54K |
| Jay S Skyler | Director | 42,500 | $4.38K |
| Stacy J. Kanter | Director | 42,500 | $4.38K |
| Corwin Dale Hooks | Chief Commercial Officer | 5,753 | $593 |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the APLT quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.